419 related articles for article (PubMed ID: 33524293)
1. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.
Bureau C; Thabut D; Jezequel C; Archambeaud I; D'Alteroche L; Dharancy S; Borentain P; Oberti F; Plessier A; De Ledinghen V; Ganne-Carrié N; Carbonell N; Rousseau V; Sommet A; Péron JM; Vinel JP
Ann Intern Med; 2021 May; 174(5):633-640. PubMed ID: 33524293
[TBL] [Abstract][Full Text] [Related]
2. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial).
de Wit K; Schaapman JJ; Nevens F; Verbeek J; Coenen S; Cuperus FJC; Kramer M; Tjwa ETTL; Mostafavi N; Dijkgraaf MGW; van Delden OM; Beuers UHW; Coenraad MJ; Takkenberg RB
BMJ Open Gastroenterol; 2020 Dec; 7(1):. PubMed ID: 33372103
[TBL] [Abstract][Full Text] [Related]
3. Eight millimetre covered TIPS does not compromise shunt function but reduces hepatic encephalopathy in preventing variceal rebleeding.
Wang Q; Lv Y; Bai M; Wang Z; Liu H; He C; Niu J; Guo W; Luo B; Yin Z; Bai W; Chen H; Wang E; Xia D; Li X; Yuan J; Han N; Cai H; Li T; Xie H; Xia J; Wang J; Zhang H; Wu K; Fan D; Han G
J Hepatol; 2017 Sep; 67(3):508-516. PubMed ID: 28506905
[TBL] [Abstract][Full Text] [Related]
4. The influence of shunting left/right portal vein branch on post-TIPS hepatic encephalopathy: a study protocol for multicenter randomized blinded controlled trial.
Ma J; Luo J; Zhang W; Zhou Y; Zhang Z; Yang M; Zhuang Z; Ma L; Yu J; Zhou X; Yan Z
Trials; 2023 May; 24(1):312. PubMed ID: 37149647
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
Riggio O; Masini A; Efrati C; Nicolao F; Angeloni S; Salvatori FM; Bezzi M; Attili AF; Merli M
J Hepatol; 2005 May; 42(5):674-9. PubMed ID: 15826716
[TBL] [Abstract][Full Text] [Related]
6. Episodic overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt does not increase mortality in patients with cirrhosis.
Nardelli S; Riggio O; Marra F; Gioia S; Saltini D; Bellafante D; Adotti V; Guasconi T; Ridola L; Rosi M; Caporali C; Fanelli F; Roccarina D; Bianchini M; Indulti F; Spagnoli A; Merli M; Vizzutti F; Schepis F
J Hepatol; 2024 Apr; 80(4):596-602. PubMed ID: 38097113
[TBL] [Abstract][Full Text] [Related]
7. Concurrent large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A randomized controlled trial.
Lv Y; Chen H; Luo B; Bai W; Li K; Wang Z; Xia D; Guo W; Wang Q; Li X; Yuan J; Cai H; Xia J; Yin Z; Fan D; Han G
Hepatology; 2022 Sep; 76(3):676-688. PubMed ID: 35266571
[TBL] [Abstract][Full Text] [Related]
8. In patients having transjugular intrahepatic portosystemic shunt, rifaximin prevented overt hepatic encephalopathy.
Koretz RL
Ann Intern Med; 2021 Jul; 174(7):JC78. PubMed ID: 34224266
[TBL] [Abstract][Full Text] [Related]
9. [Comparison of the curative effect of transjugular intrahepatic portosystemic shunt with expanded polytetrafluoroethylene-covered stent and drug combined with gastroscopy as the secondary prevention of esophageal -gastric variceal bleeding in portal hypertension].
Lin ZP; Chen SL; Wang JY; Liu F; Tan Q; Peng QF; Zhao JB
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):672-678. PubMed ID: 32911906
[No Abstract] [Full Text] [Related]
10. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
[TBL] [Abstract][Full Text] [Related]
11. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.
Lv Y; Yang Z; Liu L; Li K; He C; Wang Z; Bai W; Guo W; Yu T; Yuan X; Zhang H; Xie H; Yao L; Wang J; Li T; Wang Q; Chen H; Wang E; Xia D; Luo B; Li X; Yuan J; Han N; Zhu Y; Niu J; Cai H; Xia J; Yin Z; Wu K; Fan D; Han G;
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):587-598. PubMed ID: 31153882
[TBL] [Abstract][Full Text] [Related]
12. Comparative Efficacy of Treatment Options for the Prevention of Post-TIPS Hepatic Encephalopathy: A Systematic Review and Network Meta-analysis.
Ahmed Z; Hassan M; Arif SF; Aziz M; Iqbal U; Nawaz A; Farooq U; Smith WL; Badal J; Renno A; Javaid T; Nawras A; Saab S
J Gastrointestin Liver Dis; 2023 Apr; 32(1):70-76. PubMed ID: 37004220
[TBL] [Abstract][Full Text] [Related]
13. Prediction of mortality and overt hepatic encephalopathy undergoing transjugular intrahepatic portosystemic shunt: a retrospective cohort study.
Li K; Cheng Y; Zhao R; Jiang H; Zhang L; Tong Y; Li S
Abdom Radiol (NY); 2024 Mar; 49(3):908-918. PubMed ID: 37957372
[TBL] [Abstract][Full Text] [Related]
14. Concurrent spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: A systematic review and meta-analysis.
Yang M; Qiu Y; Wang W
Dig Liver Dis; 2024 Jun; 56(6):978-985. PubMed ID: 37926635
[TBL] [Abstract][Full Text] [Related]
15. Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial.
Pomier-Layrargues G; Villeneuve JP; Deschênes M; Bui B; Perreault P; Fenyves D; Willems B; Marleau D; Bilodeau M; Lafortune M; Dufresne MP
Gut; 2001 Mar; 48(3):390-6. PubMed ID: 11171831
[TBL] [Abstract][Full Text] [Related]
16. Rifaximin treatment in hepatic encephalopathy.
Bass NM; Mullen KD; Sanyal A; Poordad F; Neff G; Leevy CB; Sigal S; Sheikh MY; Beavers K; Frederick T; Teperman L; Hillebrand D; Huang S; Merchant K; Shaw A; Bortey E; Forbes WP
N Engl J Med; 2010 Mar; 362(12):1071-81. PubMed ID: 20335583
[TBL] [Abstract][Full Text] [Related]
17. Long-term effects and complications of the transjugular intrahepatic portosystemic shunt: a single-centre experience.
Kraglund F; Jepsen P; Amanavicius N; Aagaard NK
Scand J Gastroenterol; 2019 Jul; 54(7):899-904. PubMed ID: 31203699
[No Abstract] [Full Text] [Related]
18. Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications.
Will V; Rodrigues SG; Stirnimann G; Gottardi A; Bosch J; Berzigotti A
United European Gastroenterol J; 2020 Oct; 8(8):961-969. PubMed ID: 32588789
[TBL] [Abstract][Full Text] [Related]
19. Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage.
Sahagun G; Benner KG; Saxon R; Barton RE; Rabkin J; Keller FS; Rosch J
Am J Gastroenterol; 1997 Sep; 92(9):1444-52. PubMed ID: 9317060
[TBL] [Abstract][Full Text] [Related]
20. Covered TIPS versus endoscopic band ligation plus propranolol for the prevention of variceal rebleeding in cirrhotic patients with portal vein thrombosis: a randomised controlled trial.
Lv Y; Qi X; He C; Wang Z; Yin Z; Niu J; Guo W; Bai W; Zhang H; Xie H; Yao L; Wang J; Li T; Wang Q; Chen H; Liu H; Wang E; Xia D; Luo B; Li X; Yuan J; Han N; Zhu Y; Xia J; Cai H; Yang Z; Wu K; Fan D; Han G;
Gut; 2018 Dec; 67(12):2156-2168. PubMed ID: 28970291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
